Chemotherapy delivery
This article was originally published in The Gray Sheet
Executive Summary
Delcath Systems awaits FDA protocol approval to initiate its planned Phase III clinical trial for its catheter-based perfusion technology to deliver the chemotherapy drug melphalan after the trial was cleared by the National Cancer Institute Institutional Review Board Feb. 7. The Delcath system delivers high-dose chemotherapy directly to the liver via the hepatic artery and includes special filters that block the rest of the body from excessive toxicity, according to the firm...